Pharmaceuticals industry, Business, Science, Health, Society, UK news, US news, World news, Diabetes, NHS, Obesity, Intellectual property, Drugs Business | The Guardian
Alternatives to costly Wegovy and Saxenda will make such treatments more widely available worldwideOzempic maker invests $4bn to meet US ‘skinny jab’ demandMedicines that enable dramatic weight loss are likely to experience a new boom in uptake, experts have said, as the first generic versions hit the market this week at a lower cost than the original drugs.The injections, dubbed “skinny jabs” by the media, can help people lose more than 10% of their body weight and have become hugely popular in recent years, with celebrities lauding their effects. Continue reading…
Alternatives to costly Wegovy and Saxenda will make such treatments more widely available worldwide
Ozempic maker invests $4bn to meet US ‘skinny jab’ demand
Medicines that enable dramatic weight loss are likely to experience a new boom in uptake, experts have said, as the first generic versions hit the market this week at a lower cost than the original drugs.
The injections, dubbed “skinny jabs” by the media, can help people lose more than 10% of their body weight and have become hugely popular in recent years, with celebrities lauding their effects.
